<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Talinolol has a variable oral bioavailability of 36 to 69% in humans with physicochemical properties suitable for lipid-based self-nanoemulsifying formulations (
 <xref rid="B33" ref-type="bibr" class="xref">Terhaag et al., 1992</xref>; 
 <xref rid="B34" ref-type="bibr" class="xref">Trausch et al., 1995a</xref>; 
 <xref rid="B5" ref-type="bibr" class="xref">Elgart et al., 2013</xref>). The reduced and variable bioavailability may be attributed to precipitation of TAL in the gastro intestinal tract (GIT), incomplete and erratic absorption, and P-gp mediated efflux transport in the intestine (
 <xref rid="B10" ref-type="bibr" class="xref">Gramatte et al., 1996</xref>). It is essential to reduce the precipitation and maintain TAL solubilized in GIT to ensure its absorption in to the systemic circulation (
 <xref rid="B19" ref-type="bibr" class="xref">Mohsin et al., 2009</xref>; 
 <xref rid="B9" ref-type="bibr" class="xref">Ghai and Sinha, 2012</xref>). Solubility and dissolution is primarily the rate limiting factors for oral bioavailability of many drugs. There have been a variety of formulation strategies designed over the past two decades to improve drug solubility to enhance the rate and extent of drug absorption from the GIT (
 <xref rid="B28" ref-type="bibr" class="xref">Shahba et al., 2012</xref>, 
 <xref rid="B29" ref-type="bibr" class="xref">2016</xref>, 
 <xref rid="B27" ref-type="bibr" class="xref">2017</xref>; 
 <xref rid="B4" ref-type="bibr" class="xref">Devraj et al., 2013</xref>; 
 <xref rid="B17" ref-type="bibr" class="xref">Mohsin et al., 2016</xref>).
</p>
